Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.

TM, Ko; CY, Tsai; SY, Chen; KS, Chen; KH, Yu; CS, Chu; CM, Huang; CR, Wang; CT, Weng; CL, Yu; SC, Hsieh; JC, Tsai; WT, Lai; WC, Tsai; GD, Yin; TT, Ou; KH, Cheng; JH, Yen; TL, Liou; TH, Lin; DY, Chen; PJ, Hsiao; MY, Weng; YM, Chen; CH, Chen; MF, Liu; HW, Yen; JJ, Lee; MC, Kuo; CC, Wu; SY, Hung; SF, Luo; YH, Yang; HP, Chuang; YC, Chou; HT, Liao; CW, Wang; CL, Huang; CS, Chang; MT, Lee; P, Chen; CS, Wong; CH, Chen; JY, Wu; YT, Chen; CY, Shen

doi:10.1136/bmj.h4848

Public

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.

Shared by NobleBlocks on Sep 23, 2015 • 12:00 AM UTC

Authors:

Ko TM

Tsai CY

Chen SY

Abstract

<h4>Objective</h4>To evaluate the use of prospective screening for the HLA-B*58:01 allele to identify Taiwanese individuals at risk of severe cutaneous adverse reactions (SCARs) induced by allopurinol treatment.<h4>Design</h4>National prospective cohort study.<h4>Setting</h4>15 medical centres in di...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!